Stock market analyst Vijay Bhambwani has maintained 'buy' rating on Sun Pharmaceutical Industries Ltd stock with a target of Rs 1820-1825.

According to analyst, the investors can buy the stock with stop loss of Rs 1680.

Today, the stock opened at Rs 1755 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 65.23 and 26.62 respectively.

The share price has seen a 52-week high of Rs 1846 and a low of Rs 1159 on BSE.

Sun Pharma declared that the United States District Court for the Southern District of New York had disregarded in its total the objection lodged by Taro Pharmaceutical Ind assaying to obstruct the Tender Offer by Alkaloida Chemical Company Exclusive Group (Alkaloida), Sun's arm, to get hold of all outstanding Ordinary Taro's scrips .

Sun Pharmaceutical Ind declared that USFDA has given nod for its ANDA to sell a generic edition of Flomax, tamsulosin capsules.

Tamsulosin capsules are prescribed for treating the indications and signs of benign prostatic hyperplasia (BPH).

Sun Pharma, on July 01, has introduced the generic edition of Exelon, which is prescribed for the treatment of dementia, Alzheimer's disease and Parkinson's.